Yes, urine ACR testing is recommended for all patients with hypertension, regardless of diabetes status.
Patients with hypertension but without diabetes should undergo urine albumin-creatinine ratio (ACR) testing as part of their initial evaluation and ongoing management. This recommendation is based on current major international guidelines and strong evidence linking albuminuria to cardiovascular and kidney disease risk.
Guideline-Based Recommendations
The 2024 ESC Guidelines explicitly state: "It is recommended to measure serum creatinine, eGFR, and urine ACR in all patients with hypertension" 1. This is a Class I recommendation that applies universally to hypertensive patients, not just those with diabetes. The 2025 AHA/ACC Guidelines similarly emphasize ACR testing for risk stratification and treatment decisions in hypertensive patients 2.
Why ACR Testing Matters in Hypertension Without Diabetes
Cardiovascular Risk Stratification
- Albuminuria (ACR ≥30 mg/g) is an independent cardiovascular risk factor that predicts heart disease, stroke, and mortality even in non-diabetic hypertensive patients 3, 4
- The presence of microalbuminuria in hypertensive patients without diabetes is associated with a 2.11-fold increased risk of cardiovascular events over long-term follow-up 3
- Even low-grade albuminuria (below traditional thresholds) doubles the number of hypertensive patients identified as having increased cardiovascular risk 5
Chronic Kidney Disease Prediction
- Microalbuminuria predicts development of chronic renal insufficiency in non-diabetic hypertensive patients with a 7.61-fold increased relative risk 3
- This relationship persists even after adjusting for other risk factors, making ACR an independent predictor of kidney disease progression 3
Treatment Guidance
- ACR results directly influence medication selection: When ACR ≥30 mg/g is present with eGFR <60 mL/min/1.73 m², ACE inhibitors or ARBs are specifically recommended as they have superior efficacy in reducing albuminuria 2, 1
- A reduction in ACR of ≥30% from baseline after treatment initiation indicates effective therapy and reduced risk for both cardiovascular and kidney events 6
Practical Implementation
Initial Testing
- Obtain a spot urine sample for ACR measurement at the time of hypertension diagnosis
- This should be part of the routine initial work-up alongside serum creatinine, eGFR, lipids, glucose, and ECG 1
Follow-Up Testing
- If moderate-to-severe CKD is diagnosed (eGFR <60 mL/min/1.73 m² or ACR ≥30 mg/g), repeat measurements at least annually 1
- For patients with elevated ACR, monitoring changes after treatment initiation helps guide medication adjustments 6
Important Caveats
Variability Considerations
- Albuminuria has high intra-individual variability (median coefficient of variation 41%) 7
- Guidelines traditionally recommend confirmation with 2 out of 3 positive samples for definitive staging, though a single elevated value warrants clinical attention and consideration of treatment 7
- Higher variability tends to occur with more severe kidney disease 7
Testing Method
- Spot urine ACR is the preferred screening method—convenient, reliable, and does not require 24-hour urine collection 8
- Simple microalbumin measurement alone (without calculating the ratio) performs similarly to ACR but requires gender-specific cutoffs, making ACR the more standardized approach 8
Clinical Impact
The gap between guideline recommendations and actual practice is substantial. Research shows that ACR testing rates in hypertensive patients without diabetes remain unacceptably low (baseline 2-3% in many healthcare systems) 9. Implementation of electronic health record clinical decision support tools increased testing rates 6-fold, demonstrating both the feasibility and the current underutilization of this important test 9.
Bottom line: ACR testing in hypertensive patients without diabetes enables early detection of cardiovascular and kidney risk, guides selection of renoprotective medications (ACE inhibitors/ARBs), and allows monitoring of treatment response—all of which can alter disease progression and improve outcomes.